The genotyping market is accelerating due to breakthroughs in genomics, biotechnology, and increasing adoption across healthcare, agriculture, and personalized medicine.Austin, Dec. 07, 2024 (GLOBE ...
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% ...
CRISPR Therapeutics AG (CRSP) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
A research group led by Jacob Corn has just discovered that the use of AZD7648 has serious side effects. The study has just ...
The payment scheme will tie gene therapy payments to improvements in health outcomes—and could potentially boost the uptake ...
It's getting harder these days to find great growth stocks trading for less than $100 a share. It almost seems like a higher ...
Fmr LLC grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.0% during the 3rd quarter, ...
Antimicrobial resistance (AMR) is a critical global health crisis that undermines the effectiveness of antibiotics, leading ...
Thanks to CRISPR, our medical specialists will soon have unprecedented control over how they treat and prevent some of our ...
Genome editing with various CRISPR-Cas molecule complexes has progressed rapidly in recent years. Hundreds of labs around the ...
The gene-editing technique known as CRISPR is promising to revolutionize medicine. Some researchers are trying to help make it available for people with very rare genetic disorders.
ETH Zurich researchers have uncovered a serious side effect of using the CRISPR-Cas gene scissors. A molecule designed to make the process more efficient destroys parts of the genome.